- The disease
- Obstructive sleep apnea (OSA) is a condition in which the upper airway repeatedly collapses during sleep, causing interrupted breathing. It is associated with fragmented sleep, daytime fatigue, and, in more severe cases, cardiovascular and metabolic consequences. OSA is among the most prevalent chronic respiratory conditions globally, affecting an estimated hundreds of millions of adults (per World Health Organization estimates). Diagnosis is typically confirmed by a sleep study measuring the frequency of breathing interruptions per hour.
- What the asset is trying to do
- The AirSense 11 is a CPAP device that delivers a continuous stream of pressurised air through a mask interface to keep the upper airway open during sleep. It incorporates AutoSet technology, which adjusts delivered pressure automatically in response to detected airway events, and includes built-in connectivity for remote monitoring of therapy adherence and efficacy data (per ResMed product documentation). Unlike fixed-pressure CPAP devices, the auto-adjusting algorithm modifies pressure breath-by-breath based on real-time signals. The device is approved by the US Food and Drug Administration (FDA) for the treatment of OSA.
- What the trial is measuring, and why it matters
- The post-market clinical follow-up study (NCT06562205) is evaluating PAP (positive airway pressure) system performance in OSA patients in a crossover design comparing two device-mask configurations (per ClinicalTrials.gov NCT06562205). A separate CPAP study in stroke patients (NCT07044830) is assessing treatment outcomes from acute to chronic phases of ischemic stroke in OSA patients (per ClinicalTrials.gov NCT07044830). Post-market studies of approved devices typically assess real-world safety, mask performance, and patient adherence rather than initial efficacy, as the device has already met regulatory approval standards.
- Efficacy benchmarks in this setting
- In the OSA treatment setting, CPAP is the established first-line therapy and its efficacy benchmarks are well-documented. Landmark randomised trials have shown that CPAP reduces the apnea-hypopnea index (AHI, the number of breathing interruptions per hour) substantially compared with sham or no treatment (per Peppard et al and related literature cited in standard sleep medicine guidelines). The SAVE trial (McEvoy et al, New England Journal of Medicine, 2016) reported that CPAP did not significantly reduce the rate of cardiovascular events in patients with moderate-to-severe OSA, though it did improve snoring, daytime sleepiness, and mood scores. Given that the AirSense 11 is an approved device and the listed trials are post-market or investigator-initiated studies, early-phase data from these studies are not statistically comparable to controlled efficacy benchmarks from pivotal trials.